Trial Profile
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 04 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.